Development of a type B lantibiotic for treatment of Clostridium difficile infection (360G-Wellcome-084778_Z_08_Z)
C. difficile infection (CDI) has increased in incidence and severity through the last decade to become the major cause of mortality amongst nosocomial infections. Currently, there are very few therapeutic options for CDI and recurrence of disease after initial successful therapy is a major health problem and burden to healthcare systems.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 3500000 |
| Applicant Surname | Dawson |
| Approval Committee | Strategic Awards Committee |
| Award Date | 2008-09-16T00:00:00+00:00 |
| Financial Year | 2007/08 |
| Grant Programme: Title | Strategic Award - Innovations |
| Internal ID | 084778/Z/08/Z |
| Lead Applicant | Dr Michael Dawson |
| Other Applicant(s) | Dr Sjoerd Wadman |
| Partnership Value | 3500000 |
| Planned Dates: End Date | 2012-05-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2008-01-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | East of England |